AC Immune SA (ACIU) has released an update.
AC Immune SA has introduced a groundbreaking antibody drug conjugate (ADC) technology, named morADC, at the Alzheimer’s Association International Conference, showcasing its potential to revolutionize treatment for neurodegenerative diseases. This novel technology leverages the company’s proprietary Morphomer small molecules and SupraAntigen monoclonal antibodies to create drug-candidates with enhanced brain penetration and potency against toxic proteins in the central nervous system. The morADC platform promises to offer unique, synergistic benefits, potentially overcoming limitations of current treatments and advancing precision medicine in neurodegenerative conditions.
For further insights into ACIU stock, check out TipRanks’ Stock Analysis page.
